Prince Pharmaceutical Co (ROCO:6935) Equity-to-Asset : 0.55 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Prince Pharmaceutical Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Prince Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was NT$774.5 Mil. Prince Pharmaceutical Co's Total Assets for the quarter that ended in Dec. 2023 was NT$1,410.9 Mil. Therefore, Prince Pharmaceutical Co's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.55.

The historical rank and industry rank for Prince Pharmaceutical Co's Equity-to-Asset or its related term are showing as below:

ROCO:6935' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.47 Med: 0.51 Max: 0.55
Current: 0.55

During the past 5 years, the highest Equity to Asset Ratio of Prince Pharmaceutical Co was 0.55. The lowest was 0.47. And the median was 0.51.

ROCO:6935's Equity-to-Asset is ranked worse than
52.81% of 1087 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs ROCO:6935: 0.55

Prince Pharmaceutical Co Equity-to-Asset Historical Data

The historical data trend for Prince Pharmaceutical Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prince Pharmaceutical Co Equity-to-Asset Chart

Prince Pharmaceutical Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

0.54

0.50

0.47

0.51

0.55

Prince Pharmaceutical Co Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial			0.47	0.48	0.51	0.55	0.55

Competitive Comparison of Prince Pharmaceutical Co's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Prince Pharmaceutical Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prince Pharmaceutical Co's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Prince Pharmaceutical Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Prince Pharmaceutical Co's Equity-to-Asset falls into.

Prince Pharmaceutical Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Prince Pharmaceutical Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	774.466	/	1410.935
	=	0.55

Prince Pharmaceutical Co's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	774.466	/	1410.935
	=	0.55

Prince Pharmaceutical Co (ROCO:6935) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Prince Pharmaceutical Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Prince Pharmaceutical Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Prince Pharmaceutical Co (ROCO:6935) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Prince Pharmaceutical Co Ltd (ROCO:6935) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Number 168, Keyunnan Road, Huwei Town, Yunlin, TWN, 632

Website

https://www.prince-pharm.com.tw

Prince Pharmaceutical Co Ltd is engaged in the manufacturing, packaging, processing, and trading of various active pharmaceutical ingredients and health supplements. The company supplies its products to Taiwan, Japan, Spain, Europe, and other regions.

Prince Pharmaceutical Co (ROCO:6935) Headlines

No Headlines